This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in
subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is
believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic
vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where
this adhesion may be causally associated with worse prognosis).